BRAF and melanoma: For therapy of melanomas lacking BRAF or other targetable mutations, the chemotherapeutics paclitaxel, cisplatin and dacarbacine are in clinical use, either administered in combination or as monotherapy.7 Dacarbazine, its prodrug temozolomide, as well as fotemustine are favorably used to treat brain metastases because these inhibitors are capable of passing the blood–brain barrier.8, 9 Clinical trials combining these drugs with immunological or targeted therapies are ongoing.10, 11